Details of the Drug

General Information of Drug (ID: )

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw)
  Logarithm of the Partition Coefficient (xlogp)
  Rotatable Bond Count (rotbonds)
  Hydrogen Bond Donor Count (hbonddonor)
  Hydrogen Bond Acceptor Count (hbondacc)
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 314 mcg/L [1]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [1]
  Clearance: The apparent oral clearance of drug is 182 L/h [1]
  Elimination: Following oral administration of 320 mg radiolabelled zanubrutinib, approximately 87% of the dose was excreted in the feces and about 8% of the dose was recovered in the urine, where less than 1% of the recovered drug comprised of unchanged parent drug [1]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 4 hours [1]
  Metabolism: The drug is metabolized via the CYP3A4 [1]
  Vd: The volume of distribution (Vd) of drug is 881 L [1]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[2]

References

• [1] FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules
• [2] FDA label of Zanubrutinib. The 2020 official website of the U.S. Food and Drug Administration.